Kenneth Galbraith, Zymeworks CEO
Days after flagging its $773M takeover bid, Zymeworks minority shareholder adds AstraZeneca oncology vet to the crew
The investment firm that launched an unsolicited takeover bid for Zymeworks has now brought in an AstraZeneca vet to help devise the future strategy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.